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Enterochromaffin-like (ECL) cells are the dominant endocrine cell type in the oxyntic
mucosa. Normally regarded as histamine-producing cells, they are exquisitely sensitive to the
trophic action ofgastrin and undergo a hyperplastic increase in a variety of hypergastrinemic
conditions.
A hyperplasia-neoplasia sequence of ECL-cell proliferations has been recently proposed,
followingthe realization that increasingly severe degreesofECL-cell hyperplasias over aperiod
of several years can progress to ECL-cell carcinoids. Such carcinoids arising in patients with
chronic hypergastrinemia differ both in their clinical and pathologic profiles from the sporadic
carcinoids that occur in normogastrimenic individuals and, therefore, need to be distinguished
from them. This distinction is particularly important for their clinical management, since
antrectomy appears to be ofbenefit in ECLcarcinoids ofhypergastrinemic patients.
INTRODUCTION
As part ofthe overall structural and functional organization ofthe gastrointestinal
mucosa, the oxyntic (acid-producing) portion of the human gastric mucosa is
generously endowed with endocrine cells. Ultrastructural studies have identified at
least six distinct cell types in this endocrine cell population: the enterochromaffin
(EC) cells, the enterochromaffin-like (ECL) cells, the D cells, the D1 cells, the P, and
the X cells.
Located chiefly in the middle and lower third of the mucosal thickness, the vast
majority ofthese cells are randomly interspersed between the parietal and chiefcells
lining the oxyntic glands. While occasional endocrine cells can also be identified
between mucus neck cells in the superficial third ofthe mucosa, rare stray endocrine
cells may, in addition, be seen associated with nerve fibers and Schwann cells
(neuroendocrine complexes) in the lamina propria [1,2]. Even though these various
cell types have a random spatial distribution, it is of interest that the ECL cells are
preferentially located adjacent to the chief cells [3,4], and that their cell density
within the mucosa normally shows little, if any, regional variation. Some workers
have, however, observed the D and ECL cells to show significant age- and gender-
related variations in their total numbers [5].
These cells show immunoreactivity for such markers ofneuroendocrine differenti-
ation as chromogranin A, neuron-specific enolase, synaptophysin, pancreatostatin,
and the like. Histochemically, while these cells are argyrophil in nature, not all of
them can be simultaneously identified by any one argyrophil stain. Thus the
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Grimelius stain identifies all oxyntic endocrine cells except the D cells that show
argyrophilia only with the Hellerstrom-Hellman technique. The Sevier-Munger
technique for argyrophilia, on the other hand, selectively stains the ECL cells and a
small subsetofthe EC and D1 cells. Since, however, the relative proportion ofthe EC
and D1 cells stained by this technique is negligible, the Sevier-Munger stain is
currently relied upon for visualization of ECL cells in formalin-fixed, paraffin-
embedded tissues processed for light microscopy.
Although immunohistochemical techniques using antibodies against secretory
products of endocrine cells have now supplanted the histochemical stains for their
specific identification, thistechnique is applicable onlywhen the secretoryproductof
a particular cell type is known and present in detectable quantities. Since histamine
is either leached out, destroyed, or otherwise rendered non-immunoreactive after
formalin fixation and paraffin embedding, immunohistochemical visualization of
ECL cells requires special procedural modifications (freeze-drying, vapor-fixation,
and cryostat sectioning). This necessity has severely impaired our ability to study the
human ECLcells in routinely processed surgical pathology material, and ourcurrent
knowledge of these cells is therefore based on a composite derived from their
histochemical, immunohistochemical, and ultrastructural characteristics. Table 1
summarizes the relative numbers, secretory products (when known), histochemical,
immunohistochemical, and ultrastructural characteristics ofvarious endocrine cells
in the human oxyntic mucosa.
Interest in the pathology of oxyntic endocrine cells was serendipitously sparked
when tumors were seen to develop in the oxyntic mucosa of rats, following the
long-term administration of high doses of potent anti-secretory agents [6-10].
Originally regarded as adenocarcinomas, these tumors were reclassified as ECL-cell
carcinoidswhen Sevier-Munger stains showed the tumor cells to be argyrophil. Such
studies further showed that these ECL-cell carcinoids were accompanied by a
concomitant hyperplasia of ECL cells in the adjacent non-tumorous oxyntic mucosa
[6,7,8,11]. Subsequent workers paved the way for the gradual acceptance ofthe idea
that not only were these ECL-cell carcinoids derived from the ECL-cell hyperplasia
diffusely present in the oxyntic mucosa ofthese rats, but also that the histogenesis of
both the hyperplastic and neoplastic ECL-cell proliferations was related to the
chronic hypergastrinemia, induced by the prolonged suppression ofacid secretion in
these animals (Fig. 1).
Following the accurate categorization of these tumors and the elucidation of the
role of chronic hypergastrinemia in the pathogenesis of ECL-cell proliferations in
the rat model, attention swiftly shifted toward a systematic study ofthe human ECL
cells in order to determine if similar lesions might also develop in patients on
long-term anti-secretory therapy. This attention represented a very genuine and
pertinent concern, since these pharmacologic agents are being increasingly pre-
scribed not only for the treatment and long-term management of duodenal ulcer
disease, gastroesophageal reflux disease, and the Zollinger-Ellison (ZE) syndrome
but are also being recommended as adjuvant treatment for the eradication of H.
pylori infection [12,13]. So much scientific attention and inquiry is currently focused
on ECL cells and their proliferative lesions that these cells are now the most
extensively studied endocrine cell type in the oxyntic mucosa.
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Long-Term Administration ofGastric Anti-secretory Agents
(Ranitidine, Cimetidine, Omeprazole, etc.) to Rats
Prolonged Hypo-/Achlorhydria
Secondary Induction ofChronic Hypergastrinemia
Hyperplastic Proliferation ofECL Cells
in Oxyntic Mucosa
Progression to ECL-Cell Carcinoids
FIG. 1. Sequence of events in the induction of ECL-cell carcinoids in rats
following lifelong administration ofanti-secretory agents.
ENTEROCHROMAFFIN-LIKE (ECL) CELLS
In humans and all vertebrate species studied so far, the ECL cells are normally
confined to the oxyntic mucosa of the stomach, where they constitute its predomi-
nant endocrine cell type [11,14]. Scattered randomly in the lower and intermediate
third ofthe mucosal glands, these cells are preferentially associated with chiefcells.
In eachofthe species studied, ECLcells havebeen shownto produce histamine [15].
In man and in several other mammalian species, the ECL cells have also been
claimed to produce calbindin, a 28 kDa calcium-binding protein; gastrocalcin, a
hormone that lowers blood calcium; and the alpha subunit of human chorionic
gonadotropin (HCG) [16,17,18]. At the tissue level, ECL cells in humans are
essentially identified by their topographic distribution in the oxyntic mucosa, their
ability to stainwith the Sevier-Munger technique forargyrophilia, and theultrastruc-
tural features of their secretory granules. One of the most significant biologic
characteristics ofthe ECLcellsis theirexquisite sensitivity to the trophicinfluence of
gastrin. These cells, therefore, frequently undergo hyperplasia in chronically hyper-
gastrinemic states.
ECL-CELL HYPERPLASIA
Hyperplasia denotes a non-neoplastic (non-autonomous) proliferation of a given
cell type and implies an increase in its total cell mass. It is a morphologic phenome-
non and requires morphologic criteria for its recognition and documentation. In the
context of gastrointestinal endocrine cells in general and ECL cells in particular,
hyperplasia is currently defined as the presence ofincreased numbers (beyond twice
the standard deviation in age- and gender-matched controls) ofcells perunit area of
mucosa [19].
PROBLEMS RELATED TO THE STUDY OF ECL-CELL HYPERPLASIA
In sharp contrast toothergastrointestinal endocrine cell types, ECL-cell hyperpla-
sias have traditionally been difficult to recognize clinically because they lack correla-
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tionwith aspecific clinicalsyndrome or biochemical abnormality attributable to their
hyperfunction. Even though we now know that such hyperplasias are commonly
associated with certain clinical conditions, they are hard to detect, since they do not
produce any distinctive, endoscopically recognizable lesions that can be biopsied.
Histologically, too, they can be easily missed on routine hematoxylin and eosin
(H&E) stains unless they are specifically sought for by special histochemical and
immunohistochemical stains. In certain conditions (e.g., chronic atrophic gastritis,
pernicious anemia, and soon) associated with such hyperplasias, the involved gastric
mucosa is significantly atrophied, and it is difficult to establish if the observed
increase represents a genuine hyperplasia or a mere overcrowding related to
decreased mucosal volume. Similarly, in conditions such as the Zollinger-Ellison
syndrome, itspresence may be masked by the generalized oxyntic mucosal hypertro-
phy. Confusion related to documentation of endocrine cell hyperplasia has also
resulted from differences in the morphometric methodologies and the frames of
reference employed by earlier workers. Thus some workers have counted individual
cells, while others have used computerized point-counting techniques, and still
others have quantitated the hyperplastic population by measuring absorbance of
light and the fractional surface area of the tissue section in which such absorbance
occurs [20,21]. Results, too, have been expressed in such variable terms as absolute
cell counts per mm2 of mucosa, cells per unit length of mucosa, high-power field,
gland, or crypt as the frames ofreference [20].
MECHANISMS OF ECL-CELL HYPERPLASIA
Hyperplasias of ECL cells could theoretically result from a number of different
mechanisms, such as prolongation of their half-life, differentiation of a larger
fraction ofpluripotent stem cells into ECLcells, or the augmented self-replication of
functionally mature ECL cells. Since these mechanisms are not mutually exclusive,
ECL-cell hyperplasias could result from a combination of these mechanisms. Each
such mechanism could be triggered by a release from the normal restraining
influence of an inhibitor of endocrine cell proliferation, an interruption of the
normalphysiologicnegative feedback mechanism governing their status, the trophic
stimulation by specific regulatory peptides (e.g., gastrin) and secretagogues (e.g.,
calcium), or by autocrine mechanisms whereby cells secreting an endogenous
hormone-likegrowthfactor, forwhichthey themselves have surface receptors, could
self-stimulate their proliferative activity [6,7,22-26]. Furthermore, the local tissue
and intraluminal microenvironment (for example, gastric motility, distention, and
the intraluminal pH of the stomach) could, by influencing any one or more of these
triggering mechanisms, also play an important role in the initiation, maintenance,
and progression of the hyperplasias.
Withgradualimprovements in ourunderstanding oftheir normal physiologic role,
their interrelationships with other endo- and exocrine cell types, and their status in
various diseases, we have now come to realize that, although ECL-cell proliferations
generally do not produce a dramatic clinical syndrome, ECL-cell hyperplasias can
occur in a variety of clinical conditions. It must, however, be mentioned that,
although such hyperplasias could either be a primary event or be secondarily
induced, onlysecondaryhyperplasias ofthe ECL cells have been described so far.
Hyperplastic andneoplastic ECL-cell proliferation have been best documented in
rodents-most notably in the Mastomys sp., where they give rise to histamine-
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induced gastric and duodenal ulcers [27], and in rats, following the long-term
administration ofvarious anti-secretory agents (e.g., ranitidine, cimetidine, omepra-
zole, and so on) [6-10]. Whereas, in the Mastomys, these lesions are related to the
geneticpredisposition ofthis species to develop spontaneous tumors in theglandular
stomach and otherviscera, the ECL-cell hyperplasia observed in rats is, on the other
hand, due to the sustained hypergastrinemia induced secondarily by suppression of
acid secretion [7,26,28-30]. In fact, in the rat model not only does the severity of
hypergastrinemia correlatewith the intensityofECL-cell hyperplasia [6,7,23,29], but
these hyperplasias also undergo regression after correction of the hypergastrinemia
[31]. Recent reports that ECL-cell hyperplasias, with orwithout ECL-cellcarcinoids,
also develop in rats rendered chronically hypergastrinemic by partial corpectomy or
by exogenous gastrin infusion further support this inductive role for hypergas-
trinemia [11,32-34]. Gastrin induces its well-known trophic influence on oxyntic
mucosa by promoting both DNA synthesis and mitotic activity in the epithelial cells,
and consequently causes increased growth and weight of the mucosa [30,33,35-38].
Cell kinetic studies in rats and dogs have shown that, while hypergastrinemia
increases the labeling index in both the pluripotent stem cells of the proliferative
zone and the functionally mature ECL cells, this increase is more pronounced in the
latter [6,23,30,37,38]. These studies thus confirm that the ECL cells are preferen-
tially influenced by the mitogenic effects of gastrin, and that ECL-cell hyperplasia
results more from a replication ofmature ECLcells than their augmented derivation
from uncommitted progenitor cells.
In man, ECL-cell hyperplasias and ECL-cell carcinoids have been recognized only
recently andwere first observed in patientswith chronic atrophicgastritis, pernicious
anemia, and the ZE syndrome [39-47]. More recently, these lesions have also been
observed in patients receiving anti-secretory therapy with H2 blockers or the proton
pump inhibitor omeprazole [48,49]. In these patients, the ECL-cell hyperplasia
appears to result from hypergastrinemia that is secondarily induced by those
therapeutic agents [41]. In the oxyntic mucosa of these patients, argyrophil stains
show a spectrum ofhyperplastic lesions ranging from a diffuse increase in argyrophil
cell numbers at one end, through linear and nodular aggregates, to frank carcinoids
[4,20,50-52]. As in rats, a parallel correlation between the degree of hypergas-
trinemia and the severity of ECL-cell hyperplasia has also been observed in these
patients [51]. Such a progression from diffuse hyperplasia, through linear and
micronodular hyperplasia, to carcinoid tumors has recently been formalized into a
hyperplasia-neoplasia sequence [19] (Table 2). In this sequence, the earliest stage
(simple hyperplasia) is characterized by the presence of increased numbers of
endocrine cells scattered singly or in clusters of up to three or four cells per gland
deep in the oxyntic mucosa (Fig. 2). When quantitated morphometrically, the
number of such cells per mm2 of the oxyntic mucosa is seen to exceed 2 standard
deviations over the normal range in age- and gender-matched controls [53]. With
increasing degrees of hyperplasia, the proliferating endocrine cells align themselves
in a linear or daisy-chain-like fashion along the basement membrane of the gland;
this phase is designated as the stage oflinearhyperplasia (Fig. 3). The next recogniz-
able stage (micronodularhyperplasia) in this scheme is the earliest stage that can be
seen under the H&E stain and is characterized by the presence of small nodular
endocrine cell clusters located in the base of the oxyntic glands, abutting the
muscularis mucosae (Fig. 4). These solid micronodular clusters, with the same
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TABLE 2
Classification of Oxyntic Endocrine Cell Proliferations
Hyperplasia
Simple (diffuse)
Linear
Micronodular
Adenomatoid
Dysplasia (Pre-Neoplastic Stage)
Enlarging micronodule
Fusing micronodule
Microinvasive lesion
Nodule with newly formed stroma
Carcinoid (Neoplastic Stage)
Intramucosal carcinoid
Invasive carcinoid
average diameter as that ofa gastric gland (100-150 ,um), represent clonal prolifera-
tions of intraglandular ECL cells, since they are bounded by an intact basement
membrane contiguous with that ofthe gland. Aggregates ofseveral such micronodu-
larlesions, eachwith its intactbasementmembrane, constitute the stage ofadenoma-
toid hyperplasia (Fig. 5). Enlargement of each micronodule, with breakdown of its
basement membrane, presence of cytologic atypia, increased nuclear-cytoplasmic
ratio, and a reduction in the intensity ofargyrophilia is the hallmark ofthe dysplastic
(pre-carcinoid) lesions. These lesions, ranging between 150 microns and 0.5 mm in
diameter, can show avarietyofmorphologicvariationssuch asenlargingmicronodules
A
FIG. 2. Simple hyperplasia of argyrophil endo-
crine cells in the oxyntic mucosa of a patient with
chronic atrophic gastritis type A. Note the in-
.,>; . - * creased numbers of argyrophil cells dispersed sin-
_' gly or in small clusters ofup to three or four cells in
;;P7 the closely packed glands (Grimelius stain with
.- -,. ..'methyl green counterstain) (from [20]).
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FIG. 3. Linear hyperplasia ofargyrophil endocrine cells in the oxyntic mucosa ofa
patient with chronic atrophic gastritis type A. The markedly increased numbers of
argyrophil cells are arranged in a linear daisy-chain-like fashion along the basement
membrane of the glands (Grimelius stain with methyl green counterstain) (from
[20]).
(when nodular aggregates measure more than 150 microns in diameter), fusing
micronodules (when several adjacent micronodules fuse together to form a large
island of cells), microinvasive lesions (when clusters of atypical cells infiltrate the
lamina propria between the glands or show incipient extension into the adjacent
muscularis mucosae), and nodules with newly formed stroma (when the nodules
FIG. 4. Micronodular hyperplasia of argyrophil endocrine
cells in a patient with chronic atrophicgastritis, type A. Focal
nodular clusters of five to 25 endocrine cells, ranging up to
100 microns in size and not exceeding the diameter of the
gastric glands, are seen deep in the lamina propria, abutting
the muscularis mucosae. A fewglands also show linearhyper-
plasia of the endocrine cells (Grimelius stain with methyl
green counterstain) (from [20]).
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FIG. 5. Adenomatoid hyperplasia, showing a collection of several
micronodules deep in the oxyntic mucosa of a patient with chronic
atrophic gastritis type A. Note that, though the micronodules are in close
proximity to each other, their basement membranes are still intact
(Grimelius stain with methyl green counterstain) (from [20]).
acquire a lobular or trabecularpattern) (Fig. 6). Conceptually, the dysplastic stage is
highly significant, since it marks the borderland between the clearly hyperplastic
stages preceding it and the neoplastic (carcinoid) stage following it in the sequence.
The carcinoid stage is characterized by the presence of nodular infiltrating growths
greater than 0.5 mm in diameter. Though these lesions are completely intramucosal
4~~
FIG. 6. Dysplastic lesion, showing large irregular
-- ~~4 clusters of proliferating endocrine cells deep in the
lamina propria. These clusters lack a basement
membrane; the cells are only faintly argyrophilic
2 and show nuclear atypia (Grimelius stain with
.-.. qBtrnmethyl green counterstain) (from [20]).
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FIG. 7. Intramucosal carcinoid located deep
within the oxyntic mucosa of a patient with
Zollinger-Ellison syndrome and possibly also multi-
-,' -~~--~- K ple endocrine neoplasia type 1. Note the trabecular
arrangement of the tumor cells (hematoxylin and
eosin stains) (from [20]).
at first, they gradually extend intramurally and, with time, invade vascular or
lymphatic channels to produce nodal and distant metastases (Fig. 7).
This hyperplasia-neoplasia sequence of ECL-cell proliferation is relevant for its
implication in assessing the neoplastic potential ofECL-cell hyperplasias in different
clinical conditions and for the prognostic evaluation ofpatients at risk ofdeveloping
gastric carcinoids. The validity and reproducibility of this qualitative system of
diagnosing and grading ECL-cell hyperplasia has been confirmed in a comparative
study, wherein ECLcells in gastric mucosal biopsies were quantitated morphometri-
cally as well as independently graded for hyperplasia by the above-mentioned
criteria. It was seen that not only were the cell counts (mean + SEM = 8.3 + 1.2
cells/mm2) in the earliest stage (simple hyperplasia) well above the 2 standard
deviations of the corresponding value of 1.6 ± 0.2 cells/mm2 in age- and gender-
matched controls, but also thattherewasclose tocomplete concordance between the
two techniques [53].
The co-existence ofECL-cell carcinoids withvarious grades ofECL-cell hyperpla-
sias in the oxyntic mucosa ofhypergastrinemic patients strongly reinforces the belief
that the different hyperplastic lesions represent sequential steps in the evolution of
gastric ECL-cell carcinoids (Fig. 8). While ECL-cell carcinoids mostfrequentlyoccur
inpatientswithchronic atrophicgastritis andpernicious anemia [4,14,39,40,43,50,54-
58], they are very uncommon in the Zollinger-Ellison syndrome, even though these
patients have a more severe degree of hypergastrinemia and frequently have ECL-cell
hyperplasia in the oxyntic mucosa [14,46,54,59-61]. The few ZE patients who have
developed ECL-cell carcinoids have all had the multiple endocrine neoplastic type 1
(MEN-1) syndrome [14].
While development of ECL-cell hyperplasia in MEN-1 patients may be linked to
genetic factors, it could also be due to the antral G-cell hyperplasia that these
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.
1 i .FIG. 8. Scanningviewphotomicrograph ofoxyntic
mucosa of a patient with chronic atrophic gastritis
a type 1, showing a small carcinoid tumor with early
X8 g . 1 K submucosal invasion (arrows) arising in a back-
ground of argyrophil endocrine cell hyperplasia in
adjacent mucosa (arrowheads) (Grimelius stain with
*;*, "'E.4*Xt;i O' -fi-.2 ^W ' wmethyl green counterstain) (from [20]).
patients are known to have. Thus, MEN-1 patients may already have some degree of
secondary ECL-cell hyperplasia even before they develop hypergastrinemia from
theirgastrinomas [62]. The non-familial ZEpatients, on the otherhand, have normal
antropyloric G-cell counts [63] and therefore develop ECL-cell hyperplasia only
after the onset of their tumor-induced hypergastrinemia. Since there is a long
evolutionaryperiod ofseveral years (apparently more than ten) in the progression of
hyperplasia to neoplasia, it is possible that some of these patients may undergo a
gastrectomy in the interim [64]. Nevertheless, the occasional reports of such tumors
developing in patients with non-familial ZE syndrome indicate that ECL-cell carci-
noids can develop in these patients as well [14,47,56,65,66]. This development is
particularly germane for clinical management, since increasing numbers of ZE
patients are now being managed medically on long-term therapy with gastric acid
inhibitors and are having their gastrectomies postponed for longer and longer
periods. Furthermore, it is quite likely that, in the future, ECL-cell hyperplasias and
ECL-cell carcinoids will be detected in a variety of other chronic hypergastrinemic
states aswell [67].
ClinicalRelevance ofECL-CellHyperplasias
ECL-cell hyperplasia is seen in nearly 10 percent of patients undergoing endos-
copy for uppergastrointestinal symptoms [50]. Since these lesions are asymptomatic,
they are most often detected incidentally or when co-existent carcinoids or polyps
produce symptoms. Histologically, too, the early lesions remain undetected, unless
their presence is specifically sought for by special stains. Because these hyperplastic
lesions have the ability to develop into carcinoids which are potentially malignant
tumors, it has been suggested that ECL-cell hyperplasias should be regarded as
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)EW FIG. 9. Gastric oxyntic mucosa. Several small
20 micronodular aggregates ofclosely packed neuro- SI'>tg3^ si;E>:s2Xt>j endocrine cells are located deep in themucosa,
t> ._ >'tx*Nabutting the muscularis mucosae. These clusters
>,;b*; "-;'\.^+'s<; ,; 4 - were argyrophilic by both the Grimelius and the
9 s i ,t ffi . <Jf *Sevier-Munger techniques, and strongly immuno-
' reactiveforbothneuron-specific enolase andchro-
mogranins (hematoxylin and eosin stains) (from
j g % . > @7- ~~~~~~~~~[20]).
pre-neoplastic lesions [19]. Since, however, the clinical risklies not in the presence of
these lesions but in their progression to invasive carcinoids, it is important to bear in
mind that not all hyperplasias progress to carcinoids, and even the few that do take
several years to do so. In the absence of carcinoid tumors, these lesions should be
managed conservatively by periodic endoscopy and biopsy to monitor their progres-
sion. It should, however, be noted that the early hyperplastic lesions are radiologi-
callyandendoscopicallyundetectable [55], and eventheearliestlesions(micronodular
hyperplasia) visible on routine light microscopy are located deep within the mucosa
(Fig. 9). Quite often, they are not even included in mucosal biopsies obtained by the
usual 2-3 mm biopsy forceps. It is therefore important that multiple full-thickness
mucosal biopsies with "jumbo" biopsy forceps be obtained when patients at risk for
endocrine cell hyperplasia are being evaluated. When a carcinoid tumor develops,
management should be dictated by clinical symptomatology, and tempered by
pathologic features (size, number, location, local invasion, and so on) ofthe tumors.
ClinicalRelevance ofECL-Cell Carcinoids
In the past, gastric carcinoids accounted for 3-5 percent of all gastrointestinal
carcinoids and for 0.3 percent or less of all gastric tumors [68]. Recent studies
indicate that they now comprise between 11-30 percent of all gastrointestinal
carcinoids [69,70]. This increase in the overall incidence of gastric carcinoids,
especially in hypergastrinemic patients, maybe multifactorial: the first factor relates
mainly to whether the tumors arising in patients with chronic atrophic gastritis and
pernicious anemia may have been under- or misdiagnosed in the past. Carcinoids
arising in these patients are radiologically and endoscopically indistinguishable from
the hyperplastic and adenomatous polyps so commonly encountered in these pa-
tients [71] and may indeed even co-exist with such polyps. Since, in the pre-
816HYPERPLASTIC PROLIFERATIONS OF THE ECL CELLS
TABLE 3
Conditions Associated with Increased Risk for Multicentric Gastric Carcinoids
Chronic Atrophic Gastritis (type A)
Zollinger-Ellison (familial and non-familial) Syndrome
Patients on Pharmacologic Gastric Acid Blockade
(H2-receptors, proton pump inhibitors)
Chronic Renal Failure (±hemodialysis)
Pernicious Anemia
Autoimmune Disorders:
Diabetes mellitus, type 1 (IDDM)
Polyglandular autoimmune syndrome
Rheumatoid arthritis
Sjogren's syndrome
Addison's disease
Myxedema
IDDM: insulin-dependent diabetes mellitus
endoscopy era, such polyps were never biopsied, their true nature may never have
been established. Second, gastric carcinoids generally exhibit a solid, trabecular, or
mixed (glandular and trabecular) architecture different from that of the more
commonappendiceal andilealcarcinoids [72,73]. Sincetheselesionsareindistinguish-
able from poorly differentiated adenocarcinomas, it is possible that some of them
mayhavebeenmisdiagnosed as such [74,75]. In aretrospective analysis of140gastric
tumors originally diagnosed as adenocarcinoma, 7 percent of the tumors were
eventually reclassified as carcinoids [76]. The third factor relates to the more
widespread use of histochemical, immunohistochemical, and ultrastructural tech-
niques, all ofwhich have substantially improved our ability to diagnose these tumors
more accurately and subclassify them as to their constituent cell type. Last, but not
least important, is our increased awareness ofthe higher potential ofthese tumors to
develop in avariety ofhypergastrinemic states. Perhaps the most significant factor in
this regard is the emergence of an enlarging pool of a heterogeneous group of
hypergastrinemic patients who are at higher risk for developing gastric carcinoids.
Such a poolwould include patientswith duodenal ulcer or ZE syndrome undergoing
long-term therapy with anti-secretory agents [48,49,77,78], patients with chronic
renal failure, and those with such autoimmune disorders as insulin-dependent
diabetes mellitus (diabetes mellitus, type 1), Addison's disease, Sjogren's syndrome,
rheumatoid arthritis, autoimmune thyroiditis, the polyglandular autoimmune syn-
drome, and so on (Table 3). A significant proportion ofpatients with some of these
disorders have chronic atrophic gastritis and hypergastrinemia [42,44,79-85], while
others additionally have antibodies to parietal cells and intrinsic factor in their
circulation [80,81,86,87]. In fact, several reports documenting the association of
gastric carcinoids, achlorhydria, and hypergastrinemia in patients with diabetes
mellitus and Addison's disease have already appeared in the literature [42,44,84,88].
It is very likely, therefore, that in the future as more of those at risk are carefully
screened, both ECL-cell hyperplasias and tumors will be encountered with greater
frequency in a wider variety of hypergastrinemic states than is currently recognized
[67].
Despite the close similarities in their clinical, histologic, histochemical, and
immunohistochemical profiles, hypergastrinemia-associated gastric carcinoids differ
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TABLE 4
Comparative Profile of Gastric Carcinoids in Hyper- and Normogastrinemic Patients
Hypergastrinemia-Associated
Gastric Carcinoids
Sporadically Occurring
Gastric Carcinoids
Number
Size
ECL-Cell Hyperplasia
Neuroendocrine Markers
Chromogranin A
Synaptophysin
Pancreatostatin
NSE, and so on
Argyrophilia
Grimelius
Sevier-Munger
Regulatory Peptides
Ultrastructure
Clinical Features
Biological Behavior
Nodal metastasis
Liver metastasis
Five-year survival
Usually multicentric
Usually less than 2 cm
Diffusely present
Diffusely positive
Diffusely positive
Diffusely positive
Diffusely positive
Diffusely positive
Diffusely positive
Usually negative
Most cells negative, some positive
for 5-HT, gastrin, and so on
Secretorygranules arevacuolated and
have small eccentric cores.
Granulated coreswith thin halo
Agranulated cells with few D1 or P-
type granules
Endocrinologically silent
"Atypical carcinoid syndrome"
(Histamine)
Less aggressive
16%
4%
Invariably single
Generally more than 3 cm
Absent
Diffusely positive
Diffusely positive
Diffusely positive
Diffusely positive
Diffusely positive
Variably positive
Heterogeneous
Variably positive for 5-HT, 5-HTP,
ACTH, PMSH, and so on
Veryvariable
Endocrinologically silent
"Atypical carcinoid syndrome" (5-
HTP and 5-HT, Cushing's syn-
drome, ACTH)
More aggressive
55%
24%
50%
significantly in their biologic behavior and ultimate outcome from those arising
sporadically in normogastrinemic patients (Table 4). Thus, carcinoids in both groups
are usually asymptomatic and are generally detected incidentally during radiologic,
endoscopic, or surgical evaluation for unrelated symptoms. Tumors in hypergastrin-
emic patients are usually multiple, while those occurring sporadically in normogas-
trinemic patients are invariably solitary [14,56]. The multicentric carcinoids in
hypergastrinemic patients arise in a background of ECL-cell hyperplasia, while the
solitary ones in normogastrinemic patients do not. Quite often, the adjacent mucosa
does not even show any inflammatory or metaplastic changes. Irrespective of
whether they are solitary or multiple, carcinoids arising in oxyntic mucosa are
argyrophil by both the Grimelius and Sevier-Munger techniques, but are non-
argentaffin. Tumor cells are immunoreactive for such neuroendocrine markers as
neuron-specific enolase, chromogranins, synaptophysin, and so on, but are usually
negative for all of the common gastrointestinal regulatory peptides and biogenic
amines. Occasional tumors may, however, show immunoreactivity for serotonin,
gastrin, somatostatin, and the like in up to 10 percent of the cells [72,89-91]. In the
hypergastrinemic patients with chronic atrophic gastritis and pernicious anemia, the
occasional non-ECL-cell tumors arising fromco-existent fociofpyloric and intestinal
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metaplasia show a mixed population of cells that are immunoreactive for intestinal
hormones [42,50].
Ultrastructurally, the tumor cells in ECL-cell carcinoids of hypergastrinemic
patients show morphologically heterogeneous secretory granules that do not resem-
ble those of normal or hyperplastic ECL cells. They either have a wide halo and
small, eccentric, electron-dense cores, or show moderately electron-dense cores with
a granular interior and a thin halo [64,92]. The non-ECL-cell tumors arising in
normogastrinemicpatients, on the other hand, contain granules identical to those in
normalD1 or P cells, while the mixed tumors, referred to earlier, show cells that are
either agranular or contain granules similar to those in normal or neoplastic EC and
ECL cells [14,42,50].
Of far greater significance are the clinical and biological differences between the
two groups of tumors. Although the vast majority of gastric carcinoid tumors are
endocrinologically silent, approximately 7 percent of such tumors in hypergastrin-
emic patients are associated with an atypical carcinoid syndrome that is due to
excessive histamine production by the tumor cells [66,93,94]. The atypical carcinoid
syndrome associated with sporadic carcinoids in normogastrinemic patients is clini-
cally different and is due to the overproduction of 5-HT and 5-HTP by the tumor
cells [95,96]. The Cushing's syndrome sometimes seen in these patients is due to
excessive production ofACTH [97].
Biologically, too, the sporadic tumors appear to have a much more aggressive
clinical course. Thus, the incidence of regional lymph node metastasis (55 percent)
and hepatic metastasis (24 percent) and an overall five-year survival rate of 50
percent seen in gastric carcinoids in general [98] is in sharp contrast to the
corresponding figures of 16 percent and 4 percent for those arising in hypergastrin-
emic patients [14]. While survival figures for this latter group are not yet available,
follow-up data indicates that their prognosis, even in the presence of metastasis, is
superior to that of the sporadic group [40,44,51,99-101]. Even when such tumors
have beenincompletely excised, they have been seen, at re-exploration several years
later, not to have grown or metastasized [99]. Thus, because of differences in their
clinical and biological behavior, hypergastrinemia-associated carcinoids need to be
differentiated from those occurring sporadically in normogastrinemic patients. This
task is easily accomplished on the basis oftheir clinical and pathological features.
Role ofGastrin in the Histogenesis ofECL-Cell Carcinoids
Considerable clinical and experimental evidence has now accumulated to indicate
that prolonged hypergastrinemia is an important, ifnot the primary, causative factor
in the histogenesis of ECL-cell hyperplasias and the multicentric ECL carcinoids
[4,6-10,14,23,41,45,50,51,54,57,58,102]. Sincegastriccarcinoids develop in normogas-
trinemic patients as well, it is clear that not all gastric carcinoids are gastrin-
dependent fortheirhistogenesis[4,50]. Since carcinoids innormogastrinemic patients
do not arise from an antecedent endocrine cell hyperplasia, it is likely that they are
either only partly gastrin-dependent or are dependent on factors other than gastrin
for their histogenesis [4,50].
Although clarification of the role ofhypergastrinemia in ECL-cell proliferations
has enhanced our understanding of how multicentric gastric carcinoids develop, it
has also fueledcontroversyregarding their clinicalmanagement. The most pertinent
issues revolve around whether an antrectomy performed for such tumors has any
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beneficial effects on the reversibility of ECL-cell hyperplasias and whether it
influences the biological progression of these hyperplastic lesions to carcinoidogene-
sis. In this context, two factors need to be borne in mind. First, not all endocrine cell
hyperplasias inevitably evolve into carcinoids, and even the few that do are slow to do
so. Second, while hypergastrinemic patients are inherently at risk for developing
such proliferative lesions in their oxyntic mucosa, it has not been conclusively shown
that patients on prolonged anti-secretory therapy are rendered more prone to
develop these tumors as a result of such therapy. Neither has it been shown that the
few tumors that have developed in such patients [77,78] are any more aggressive
biologically than those developing in patients with hypergastrinemia from other
causes. Furthermore, since only a small number of patients have received long-term
therapy with these agents, their annual or cumulative risk for developing gastric
carcinoids cannot be assessed, as yet. The situation needs to be carefully monitored
and shall, it is hoped, be clarified as more data become available in the future.
The Role ofAntrectomy in Clinical Management ofECL-Cell Hyperplasias
and Carcinoids
Antrectomy is now known to lead to a regression or complete disappearance of
both ECL-cell hyperplasias and gastric carcinoids in hypergastrinemic patients
[58,90,103,104]. A recent report even documents a spontaneous regression of these
tumors [105]. Antrectomy, either performed surgically or through pharmacologic
manipulations using somatostatin or its synthetic analogs, is therefore being advo-
cated for the treatment of gastrin-dependent carcinoid tumors. On account of its
inhibitory action on gastrin release, therapy with somatostatin or its long-acting
synthetic analog appears to hold promise in hypergastrinemic patients. Although a
variety of gastrointestinal and pancreatic endocrine tumors have been treated with
these agents [106,107], their effects on ECL-cell hyperplasias have not been studied
as yet. Surgical antrectomy, on the other hand, is based on sound physiologic
principles and would appear to be an appropriate treatment for these lesions.
Since, however, the sporadic non-ECL cell, and the metaplastically derived
mixed-cell carcinoids of the oxyntic mucosa are not gastrin-dependent, antrectomy
would not be the most appropriate therapy for these tumors. Because these latter
tumors can be easily differentiated from the gastrin-dependent ones by their
histochemical, immunohistochemical, and electron microscopic profiles, and the
presence or absence of ECL-cell hyperplasia in the adjacent non-tumorous mucosa,
a detailed work-up of gastric carcinoids should be routinely performed before any
therapeutic decisions are undertaken.
To be of benefit, antrectomy should, therefore, be considered in patients with
advanced stages of ECL-cell hyperplasia alone, and those in whom ECL-cell
carcinoids occur in a background of ECL-cell hyperplasia. On the basis of our
current knowledge, it would appear that antrectomy should ideally be performed
before carcinoids have developed. The latest stage in which surgical antrectomy may
have an interceptive effect on the development of gastric ECL-cell carcinoids would
probably be the stage of adenomatoid hyperplasia, and surgery should definitely be
performed before invasive carcinoids have developed. Histological differentiation
between adenomatoid nodules and small carcinoid tumors can, at times, be difficult,
and all such lesions need to be interpreted with caution.
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